Press release content from Business Wire. The AP news staff was not involved in its creation.
Genprex Announces Formation of Clinical Advisory Board
February 8, 2021 GMT
AUSTIN, Texas (BUSINESS WIRE) Feb 8, 2021
Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the formation of a Clinical Advisory Board (CAB) to support its oncology and diabetes development programs. Comprised of preeminent clinical specialists, the CAB will lead and advise Genprex as it advances its REQORSA™ immunogene therapy program, including its Acclaim clinical trials in non-small cell lung cancer, and its preclinical diabetes gene therapy program. Some of the members also serve in additional roles at the Company.
The Healthcare Leadership Council issued the following news:
Experts from across healthcare have identified specific policy and regulatory recommendations to improve the nation s ability to prepare for and respond to future health crises. The recommendations are part of a new report released by the
Healthcare Leadership Council and
Duke-Margolis Center for Health Policy and result from collaboration with more than 100 private-sector, nonprofit, and government organizations and stakeholders to assess the response to COVID-19 and the nation s existing disaster preparedness infrastructure.
The recommendations include some temporary steps taken to address the COVID-19 pandemic, which have proven beneficial and should be made permanent going forward, the experts say. These include making it easier for public and private organizations to work in partnership, prioritizing supply chain readiness before crises arise, streamlining regulations that allow providers to practice medicine whe
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience. Necessary
Biden removes Sean Conley, the White House physician accused of misleading the public about Trump s COVID-19 diagnosis insider@insider.com (Bill Bostock)
President Joe Biden removed Dr. Sean Conley, Trump s White House physician.
Dr. Kevin O Connor, Biden s longtime physician, will assume the role.
Conley was accused of concealing information about Trump s condition after he got COVID-19.
Biden named Dr. Kevin O Connor the chief White House physician instead.
O Connor has been Biden s doctor since 2009 and served while Biden was the vice president, ABC News reported.
Conley is to start a teaching post at the Uniformed Services University of the Health Sciences in Maryland, the AP said.
Biden named Dr. Kevin O Connor the chief White House physician instead.
O Connor has been Biden s doctor since 2009 and served while Biden was the vice president, ABC News reported.
Conley is to start a teaching post at the Uniformed Services University of the Health Sciences in Maryland, the AP said.
Conley, who was appointed by President Donald Trump in 2018, was accused of misleading the public about Trump s COVID-19 diagnosis in October.
Conley was criticized as lacking transparency when he gave updates about Trump s condition, declining to say whether Trump had been given oxygen. He was also accused of exaggerating the president s health at the time.